Business Wire

Horizon3.ai Raises $100M to Cement Leadership in Autonomous Security

10.6.2025 12:30:00 CEST | Business Wire | Press Release

Share

Horizon3.ai, the company behind the NodeZero® Autonomous Security Platform, today announced a $100 million Series D funding round led by NEA, with participation from SignalFire, Craft Ventures and 9Yards Capital. As part of the investment, Lila Tretikov, Partner and Head of AI Strategy at NEA and former Deputy CTO of Microsoft, will join the Horizon3.ai Board of Directors.

“Over the past four years, we’ve proven that using AI to hack companies isn’t science fiction—it’s real, and it’s delivering measurable results at scale. There are now over 3,000 organizations using NodeZero globally to conduct penetration tests. We’re sustaining 100%+ year-over-year ARR growth, and we are now Rule of 40-positive, which means we’re not just growing—we’re growing efficiently,” said Snehal Antani, CEO and Co-founder of Horizon3.ai. “This raise marks the next chapter in our mission to lead the Autonomous Security category.”

“Security teams are tired of chasing CVEs, false positives, and compliance checkboxes. They want to find and fix what actually matters, verify it’s resolved, and go home early,” said Antani. “The hardest part of the job as a CIO is deciding what not to fix. The second hardest part is proving to the board that your security initiatives are meaningfully reducing risk. NodeZero plays a critical role in reducing your threat exposure over time.”

Targeting an $80B Total Addressable Market: Autonomous Security

The cybersecurity market is undergoing a generational shift. NodeZero successfully compromised a bank in 4 minutes with no humans required, far faster than the reaction time of the bank’s security team and their best-in-class tools. Similarly, adversaries are leveraging AI to exponentially increase the sophistication, complexity, speed and scale of attacks. The Horizon3.ai thesis is simple: the future of cyber will be algorithms fighting algorithms—at machine speed—with humans by exception. This requires a fundamental rebuild of every part of the cybersecurity stack. And to do so effectively, you need a deep understanding of how attackers operate—and an AI system that can use offensive insights to drive defensive improvements. Horizon3.ai is leading this shift.

“Horizon3.ai has already realized what others are just beginning to imagine. NodeZero is a fully autonomous security system operating in live production environments—executing real attacks, uncovering real risk, and delivering real results,” said Antani.

Powered by reinforcement learning, graph reasoning, and AI, NodeZero doesn't simulate adversaries—it thinks and acts like one. Each cyber attack against production systems executed by NodeZero collects training data used to improve its algorithms, creating a compounding data advantage that no other platform can match. This is the foundation for the next era of cybersecurity, where AI doesn’t just find risk, but continuously improves defenses. Horizon3.ai isn’t chasing the future—it’s building it.

Use of Proceeds: Accelerating Toward the Future

With this funding, Horizon3 is accelerating across three strategic fronts:

  • Scale through partners – Doubling down on its partner ecosystem to meet growing demand across the Americas, EMEA, and APAC.
  • Product innovation – Expanding into web application pentesting, vulnerability management, and precision defense, where NodeZero can remediate findings and tune defensive tools.
  • Winning the federal market – Scaling its success with the Defense Industrial Base through the NSA’s Continuous Autonomous Pentesting (CAPT) program, accelerating FedRAMP High usage, and expanding into Secret and Top Secret workloads to help secure the nation’s most mission-critical systems.

“What drew us to Horizon3.ai is the clarity of their mission and the speed at which they’re executing it,” saidAaron Jacobson, Partner at NEA. “They are defining a new security category—autonomous security—and are already the go-to solution for red and blue teams alike. We’re thrilled to lead this round and support the company’s next phase of growth.”

“Snehal and the Horizon3.ai team are tackling one of the biggest problems in cybersecurity: automating both sides to ensure maximum defensibility against automated and AI-driven attacks,” said Lila Tretikov, Partner and Head of AI Strategy at NEA. “Their customers love NodeZero, and the team has proven to operate with excellence at scale, which is why Horizon3.ai is transforming how security is done. I’m excited to join the board and help shape this next chapter.”

The impact is immediate and measurable. In one recent pentest, NodeZero gained access to sensitive US aircraft carrier design data through a third-party supplier. No humans were involved in the pentest. The platform autonomously compromised the network, gained access to sensitive data, and then guided defenders on exactly what to fix to prevent a breach.

“My old boss used to say, ‘don’t tell me we’re secure, show me, then show me again tomorrow, and again next week, because our environment is always changing and the enemy always has a vote,’” said Antani.

To learn more about NodeZero visit www.horizon3.ai.

For media inquiries and interviews, please see the Media Contact below.

About Horizon3.ai

Horizon3.ai is the leader in autonomous security. Our platform, NodeZero, continuously finds and exploits real-world attack paths so defenders can fix what matters and prove they’re secure. Founded by former U.S. Special Operations cyber operators and enterprise security leaders, Horizon3.ai is trusted by over 3,000 organizations worldwide—from Fortune 500 companies to national defense partners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610254822/en/

Contacts

Media Contact:
Ed Kraft
SourceCode Communications
horizon3@sourcecodecomms.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye